Advertisement

Topics

Ascletis and BeiGene Trade Lower Following Hong Kong IPOs

01:58 EDT 11 Aug 2018 | ChinaBio Today

So far, two young China biopharmas have debuted on the Hong Kong exchange, encouraged by the much-heralded new IPO rules for pre-revenue companies. Unfortunately, the market's response has been lukewarm. Ascletis raised $400 million, about the middle of its projected range, but after a week and a half of trading, the company's new shares have declined 15%. BeiGene raised $900 million, pricing the offering at the bottom of the range (and a small discount to its NASDAQ quote). It has declined 5% from its offering price in three trading sessions. There are six other pre-revenue China biopharmas that have filed for Hong Kong IPOs and several more planning to do so. The post-IPO performance of the first two could dampen the pricing of these offerings. More details....

Stock Symbols: (HK: 1672) (NSDQ: BGNE; HK: 6160)

Share this with colleagues:

Original Article: Ascletis and BeiGene Trade Lower Following Hong Kong IPOs

NEXT ARTICLE

More From BioPortfolio on "Ascletis and BeiGene Trade Lower Following Hong Kong IPOs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...